Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 276

1.

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L.

Ann Rheum Dis. 2013 Aug;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844. Epub 2013 Jun 5.

PMID:
23740227
2.

Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.

Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D'Cruz DP.

Lupus. 2013 May;22(6):574-82. doi: 10.1177/0961203313483376. Epub 2013 Apr 30.

PMID:
23632989
3.

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.

Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP.

Nephrol Dial Transplant. 2009 Jul;24(7):2157-60. doi: 10.1093/ndt/gfp002. Epub 2009 Jan 29.

PMID:
19179411
4.

Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.

Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.

Rheumatology (Oxford). 2014 Sep;53(9):1570-7. doi: 10.1093/rheumatology/ket462. Epub 2014 Feb 6.

PMID:
24505125
5.

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.

Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL.

Ann Rheum Dis. 2016 Jan;75(1):30-6. doi: 10.1136/annrheumdis-2014-206456. Epub 2014 Dec 30.

6.

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.

F L, Y T, X P, L W, H W, Z S, H Z, Z H; MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group.

Lupus. 2008 Jul;17(7):622-9. doi: 10.1177/0961203308089428.

PMID:
18625634
7.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group.

Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.

8.

Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.

Lanata CM, Mahmood T, Fine DM, Petri M.

Lupus. 2010 Jul;19(8):935-40. doi: 10.1177/0961203310365714. Epub 2010 Apr 13.

PMID:
20388722
9.

Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.

Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, Kaneko Y, Maeshima A, Kuroiwa T, Nojima Y.

Mod Rheumatol. 2014 Jul;24(4):618-25. doi: 10.3109/14397595.2013.844397. Epub 2013 Oct 21.

PMID:
24252014
10.

Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.

Mejía-Vilet JM, Arreola-Guerra JM, Córdova-Sánchez BM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R.

J Rheumatol. 2015 Nov;42(11):2082-91. doi: 10.3899/jrheum.150395. Epub 2015 Sep 15.

PMID:
26373566
11.

Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.

Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM.

Arthritis Res Ther. 2010;12(6):R208. doi: 10.1186/ar3184. Epub 2010 Nov 9.

12.

Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis.

Pinto-Peñaranda LF, Duque-Caballero V, Márquez-Hernández JD, Muñoz-Grajales C, Velásquez-Franco CJ.

Clin Rheumatol. 2015 May;34(5):897-903. doi: 10.1007/s10067-015-2864-7. Epub 2015 Jan 17.

PMID:
25592376
13.

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L, Cairns T.

Nephrol Dial Transplant. 2009 Dec;24(12):3717-23. doi: 10.1093/ndt/gfp336. Epub 2009 Jul 17.

PMID:
19617257
14.

Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.

Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, Webster AC.

Am J Kidney Dis. 2013 Jan;61(1):74-87. doi: 10.1053/j.ajkd.2012.08.041. Epub 2012 Nov 22.

PMID:
23182601
15.

The effectiveness and safety of mycophenolate mofetil in lupus nephritis.

Elyan M, Ballou S.

Clin Rheumatol. 2009 Jul;28(7):835-40. doi: 10.1007/s10067-009-1163-6. Epub 2009 Mar 25.

PMID:
19319623
16.

Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.

Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N.

Nephrol Dial Transplant. 2012 Apr;27(4):1467-72. doi: 10.1093/ndt/gfr484. Epub 2011 Sep 13.

PMID:
21917733
17.

Long-term outcome of patients with lupus nephritis: a single center experience.

Rasić S, Srna A, Uncanin S, Dzemidzić J, Rebić D, Muslimović A, Rakanović-Todić M, Hamzić-Mehmedbasić A.

Bosn J Basic Med Sci. 2010 Apr;10 Suppl 1:S63-7.

18.

Single-dose rituximab in refractory lupus nephritis.

Kotagiri P, Martin A, Hughes P, Becker G, Nicholls K.

Intern Med J. 2016 Aug;46(8):899-901. doi: 10.1111/imj.13136.

PMID:
27242250
19.

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group.

Ann Rheum Dis. 2010 Dec;69(12):2083-9. doi: 10.1136/ard.2010.131995. Epub 2010 Sep 10.

20.

Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.

Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H.

Ren Fail. 2008;30(9):865-9. doi: 10.1080/08860220802353843.

PMID:
18925525

Supplemental Content

Support Center